Clinical applications of hematopoietic growth factors

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J M Vose, J O Armitage

Abstract

To review the current clinical uses, ongoing investigations, and future applications of hematopoietic growth factors. Approved cytokines, as well as cytokines not yet released for general use, are included in this review. Clinical applications of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin, the three recombinant hematopoietic growth factors currently commercially available for clinical use in the United States, are discussed. Macrophage colony-stimulating factor (M-CSF), interleukin-3 (IL-3), PIXY321, stem-cell factor (SCF), IL-1, IL-6, and IL-11 represent cytokines not yet approved; the majority of these newer agents have their principal action at an earlier time point in the hematopoietic cascade than the currently approved cytokines. Current clinical uses of hematopoietic growth factors include decreasing cytopenias associated with chemotherapy, those due to congenital or acquired bone marrow failure states, those that occur after high-dose chemotherapy and bone marrow transplantation, peripheral-blood progenitor mobilization, and supportive care of leukemia patients. Hematopoietic growth factors have made a significant impact on the prevention ...Continue Reading

Citations

Jul 1, 1998·International Reviews of Immunology·W S Alexander
Sep 1, 1997·Seminars in Surgical Oncology·W A See, C J Berman
Jan 19, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E VoogG Salles
Mar 31, 2005·Phytotherapy Research : PTR·Rajesh AroraRakesh Kumar Sharma
Apr 16, 1998·American Journal of Clinical Oncology·J NemunaitisD R Brocks
Jan 1, 1997·Pediatric Hematology and Oncology·D Schuler
Jun 15, 1999·Toxicologic Pathology·J C Schuh, P J Morrissey
Jan 1, 1996·Vox Sanguinis·Y M Miller, H G Klein
May 18, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Curtis L CooperGary Garber
Apr 9, 2013·Journal of Tissue Engineering and Regenerative Medicine·Pedro Z AndradeCláudia L da Silva
Mar 21, 1997·The Journal of Biological Chemistry·R K TangiralaO Quehenberger
Dec 27, 2008·Bulletin of Experimental Biology and Medicine·A M DygaiE D Goldberg
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcie TomblynUNKNOWN Centers for Disease Control and Prevention
Oct 15, 2009·European Journal of Pharmacology·Andrzej SwierniakJaroslaw Smieja

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.